Provision of Novel Technology for Detection and Resistance Identification of GU Diseases

About

Public Health England awarded a contract to SpeeDx Limited for the provision of unique kits for detection and resistance identification of genital ulcer disease (GU) diseases.

The contract includes VHS (Varicella/Herpes/Syphilis) for diagnosis of genital ulcer disease, ResistancePlus MG for macrolide resistance testing of MG screen positive samples, ResistancePlus GC for ciprofloxacin sensitivity of GC NAAT positive samples, and unique FastFinder software for analysis of different assays performed individually or simultaneously to streamline workflow.

The tests will be initially purchased for PHE Bristol but the contract covers all sites nationwide.

The estimated initial volumes of VHS are around 10,000 tests per annum but are likely to increase.

The volumes of ResistancePlus kits will depend on diagnostic requirements.

The products are based on patented technology (PlexPrime®, PlexZyme®, ResistancePlus®) and a unique combination (Varicella/Herpes/Syphilis) of CE/IVD validated PlexPCR VHS tests.

The contract value is £380,000 and is awarded for 2 years with 3 possible extensions by 12 months each.